Literature DB >> 23159391

Primary small bowel malignancy: a 10-year clinical experience from Southern Taiwan.

Chung-Yueh Lin, Seng-Kee Chuah, Shih-Ho Wang, Wei-Chen Tai, Chih-Chi Wang.   

Abstract

BACKGROUND/AIMS: The difficulty in establishing early definitive diagnosis and treatment of primary small bowel malignancy (PSBM) is a challenge for clinicians. This study aimed to analyze the symptomatology, diagnosis and outcomes of PSBM.
METHODOLOGY: A retrospective chart review study was conducted on 49 patients who underwent surgical treatment for PSBM at a tertiary hospital between May 2000 and January 2010.
RESULTS: The patients with PSBM had non-specific clinical symptoms. Major diagnostic tools in the current study were computed tomography (CT) (n=40), gastrointestinal series radiography (n=10), angiography (n=5), double-balloon enteroscopy (n=3), gastroduodenoscopy (n=2), magnetic resonance imaging (n=1) and exploratory laparotomy (n=8). Gastrointestinal stromal tumor (GIST) was the most common PSBM (n=21), followed by lymphoma (n=14), adenocarcinoma (n=8), leiomyosarcoma (n=3) and sarcoma (n=3). The overall 5-year cumulative survival rate of the patients with PSBM was 57.1% with a mean survival time of 31.8±7.8 months. The 5-year cumulative survival rates for the different PSBMs were 79.1%, 46.9% and 33.2% for GIST, adenocarcinomas and lymphomas, respectively (p=0.087).
CONCLUSIONS: CT is very useful in detecting PSBM. Poor prognosis in PSBM patients detected by CT or angiography could be the result of delayed diagnosis prior to the procedure.

Entities:  

Mesh:

Year:  2012        PMID: 23159391     DOI: 10.5754/hge12893

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  Interventional digital subtraction angiography for small bowel gastrointestinal stromal tumors with bleeding.

Authors:  Yao-Ting Chen; Hong-Liang Sun; Jiang-Hong Luo; Jia-Yan Ni; Dong Chen; Xiong-Ying Jiang; Jing-Xing Zhou; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.